NCT05623787Active, not recruiting
Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms
Diagnostic Value of Diffusion-weighted Magnetic Resonance Imaging for Detection of Peritoneal Recurrence in Patients With High-risk Colorectal and Appendiceal Neoplasms : a Pilot Study
Source: ClinicalTrials.gov · Last updated 20 Mar 2025
Brief summary (registry, in English)
Diffusion-weighted magnetic resonance imaging (DWI/MRI) has been described in recent literature as a highly sensitive and specific modality for the detection of peritoneal metastases PM. It has been demonstrated to be superior to CT for patients with known peritoneal disease from colorectal and gynaecological malignancies as a staging tool for cytoreductive surgery. It was also demonstrated to be superior for the detection of PM for gastric cancer patients otherwise considered with a resectable tumor. However, the literature is scarce on the role of DWI/MRI in the detection of peritoneal recurrence for patients with high-risk features, either colorectal cancer (CRC) or appendiceal neoplasms (AN). The aim of this study is to prospectively assess the added value of whole-body DWI/MRI (WB-DWI/MRI) to CT and diagnostic laparoscopy for detection of PM in the follow-up of patients presenting with CRC or AN and high-risk features for peritoneal recurrence and evaluate how it correlates with intraoperative findings.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 10 Nov 2022
- Start date
- 1 Sept 2022
- Primary completion date
- 30 Sept 2024
- Lead sponsor
- Laval University
- Diseases
- Colorectal cancer
- NCT number
- NCT05623787
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 1 Sept 2022 to the primary completion date, 30 Sept 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient unfit for cytoreductive surgery, if required (ECOG 2 or more).
Other
- Unresected synchronous peritoneal metastases at referral.
- Low grade Appendiceal Mucinous Neoplasm (LAMN).
- No high-risk feature for peritoneal recurrence.
- Evidence of distant metastases on preoperative imaging.
- Patient who is unable to have MRI.
Who the study is looking for
- Confirmed diagnosis of colorectal cancer or high-risk appendiceal neoplasm (High grade Appendiceal Mucinous Neoplasm (HAMN), goblet-cell carcinoma or adenocarcinoma).
- No evidence of residual peritoneal disease based on referring surgeon operating report and preoperative imaging.
- At least one high-risk feature for peritoneal recurrence, including:
- Synchronous peritoneal metastases resected at index surgery;
- Synchronous ovarian metastases resected at index surgery;
- Perforated primary tumor.
- No evidence of distant metastases.
- Patient fit for cytoreductive surgery, if required (ECOG 0 or 1).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CIUSSS de l'Est-de-l'Île-de-Montréal Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
| CHU de Quebec Coordinator of this site? Confirm its status | Québec | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.